26.05

6.96% -1.95

Pre-market: 26.70 0.65 +2.50%

Cassava Sciences Inc (SAVA)

Overview News Price History Option Chain Financials Why SAVA Down? Discussions Forecast Stock Split Dividend History

Cassava Sciences Inc stock is traded at $26.05, with a volume of 1.82M. It is down -6.96% in the last 24 hours and down -10.17% over the past month. Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Previous Close:

$28.00

Open:

$28.13

24h Volume:

1.82M

Relative Volume:

1.13

Market Cap:

$1.25B

Revenue:

Net Income/Loss:

$-97.22M

P/E Ratio:

-11.89

EPS:

-2.19

Net Cash Flow:

$-82.44M

1W Performance:

+3.46%

1M Performance:

-10.17%

6M Performance:

+17.90%

1Y Performance:

+14.00%

1-Day Range:

$25.72

$28.28

1-Week Range:

$25.40

$29.49

52-Week Range:

$8.79

$42.20

Cassava Sciences Inc Stock (SAVA) Company Profile

Name

Cassava Sciences Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

512-501-2444

Address

6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

SAVA's Discussions on Twitter

Compare SAVA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SAVA	26.05	1.25B	0	-97.22M	-82.44M	-2.19
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-16-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-15-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-27-21	Initiated	B. Riley Securities	Buy
Feb-16-21	Reiterated	H.C. Wainwright	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-23-20	Upgrade	H.C. Wainwright	Neutral → Buy
May-18-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-20	Downgrade	Maxim Group	Buy → Hold
Jan-10-20	Reiterated	Maxim Group	Buy

View All

Cassava Sciences Inc Stock (SAVA) Latest News

Nov 19, 2024

Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? - MSN

Nov 19, 2024

Nov 18, 2024

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer - citybiz

Nov 18, 2024

Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer - Marketscreener.com

Nov 18, 2024

Nov 15, 2024

Anavex, Cassava Sciences, Panax Ginseng, And Long-Term Treatment Of Alzheimer's Disease - Seeking Alpha

Nov 11, 2024

Nov 10, 2024

How To Trade (SAVA) - Stock Traders Daily

Nov 10, 2024

Nov 09, 2024

Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Cassava Sciences (NASDAQ:SAVA) Issues Quarterly Earnings Results - MarketBeat

Nov 09, 2024

Cassava Sciences (NASDAQ:SAVA) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 09, 2024

Nov 08, 2024

Cassava Sciences Q3 2024 Earnings Preview - MSN

Nov 08, 2024

Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - Benzinga

Nov 08, 2024

Another U.S. biotech based on Chinese science - STAT

Nov 08, 2024

Cassava Sciences: With Almost Half The Float Shorted, Results Could Be Interesting - Seeking Alpha

Nov 08, 2024

Cassava Sciences nears Alzheimer's drug trial results By Investing.com - Investing.com Canada

Nov 08, 2024

Cassava Sciences’ Q3 2024: Financials and Alzheimer’s Trials Progress - TipRanks

Nov 08, 2024

Nov 07, 2024

Cassava Sciences: Pivotal Alzheimer’s Data May Push Stock Toward Book Value (SAVA) - Seeking Alpha

Nov 07, 2024

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh (NASDAQ:SAVA) - Seeking Alpha

Nov 07, 2024

Looking At Cassava Sciences's Recent Unusual Options Activity - Benzinga

Nov 07, 2024

Cassava Sciences nears Alzheimer's drug trial results - Investing.com India

Nov 07, 2024

Cassava Sciences stock in focus after earnings (SAVA:NASDAQ) - Seeking Alpha

Nov 07, 2024

Cassava Sciences Reports Q3 2024 Financial and Operating Results - The Manila Times

Nov 07, 2024

Nov 06, 2024

Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024

Nov 05, 2024

Cassava Sciences (NASDAQ:SAVA) Trading Down 5.8%Should You Sell? - MarketBeat

Nov 05, 2024

Unpacking the Latest Options Trading Trends in Cassava Sciences - Benzinga

Nov 05, 2024

Nov 04, 2024

Analysts Believe Cassava Sciences Now Has 300% Upside From Here - MSN

Nov 04, 2024

Nov 01, 2024

Cassava Sciences (SAVA) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 01, 2024

Oct 31, 2024

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 - GlobeNewswire

Oct 31, 2024

International Assets Investment Management LLC Makes New Investment in Cassava Sciences, Inc. (NASDAQ:SAVA) - MarketBeat

Oct 31, 2024

Oct 30, 2024

Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value - Yahoo Finance

Oct 30, 2024

Long Term Trading Analysis for (SAVA) - Stock Traders Daily

Oct 30, 2024

Oct 26, 2024

HC Wainwright & Co. Upgrades Cassava Sciences (SAVA) - MSN

Oct 26, 2024

Oct 24, 2024

Cassava Sciences Options Trading: A Deep Dive into Market Sentiment - Benzinga

Oct 24, 2024

Oct 21, 2024

Institutions profited after Cassava Sciences, Inc.'s (NASDAQ:SAVA) market cap rose US$72m last week but individual investors profited the most - Simply Wall St

Oct 21, 2024

Oct 19, 2024

(SAVA) Proactive Strategies - Stock Traders Daily

Oct 19, 2024

Oct 17, 2024